WGS Dec 2024 35.000 call
| Previous close | 6.27 |
| Open | 6.27 |
| Bid | 5.00 |
| Ask | 5.80 |
| Strike | 35.00 |
| Expiry date | 2024-12-20 |
| Day's range | 6.27 - 6.27 |
| Contract range | N/A |
| Volume | |
| Open interest | 86 |
Simply Wall St.Insiders Buying GeneDx Holdings Might Wish They Invested More, Stock Gains 12%
GeneDx Holdings Corp. ( NASDAQ:WGS ) insiders who bought shares over the past year were rewarded handsomely last week...
GlobeNewswireGeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that it is expanding access to its rapid whole genome sequenci
- GlobeNewswire
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients. “Receiving a genetic diagnosis can be critical in a child’s journey toward effective treatment and care, and we are thrilled our biopharma counterpar
